Abstract:METHODS: HepG2/mdr1 was obtained by cloning the whole gene mdr1 into HepG2 cells. shRNA targeting sequence was designed to be homologous to the P-gp encoding MDR1 mRNA consensus sequence. pSUPER-shRNA/mdr1 was constructed using the enzyme-digested technique. HepG2/mdr1 cells were transfected with vectors of pSUPER-shRNA/mdr1 to measure their efficacy by real-time PCR for mdr1 mRNA, flow cytometry (FCM) for P-gp expression, and Rhodamine efflux, MTT method for HepG2/mdr1 function, respectively. In vivo, mice tumors were treated by injecting pSUPER-shRNA/mdr1 in situ and into intraabdominal cavity. Tumors were collected to create cell suspension and cryosections after chemothearpy with adiramycin and mytomycin. The cell suspension was incubated in RPMI-1640 supplemented with G418 to screen stable cells for appreciating the reversal of MDR. Cryosections were treated with immunohistochemistry technique to show the effectiveness of transfection the expression of P-gp.RESULTS: pSUPER-shRNA/mdr1 was successfully constructed, which was confirmed by sequencing. The MDR phenotype of HepG2/mdr1 was decreased significantly in vitro transfection. HepG2/mdr1 showing its MDR was reversed notably in P-gp expression (11.0% vs 98.2%, P < 0.01). Real-time PCR showed that mRNA/mdr1 was lower in test groups than in control groups (18.73 +/- 1.33 vs 68.03 +/- 2.21, P < 0.001). Compared with HepG2, the sensitivity of HepG2/mdr1 and HepG2/mdr1-dsRNA cells to ADM was decreased by 1.64 times and 15.6 times, respectively. The accumulation of DNR in positive groups was decreased evidently. In vivo, the p-gp expression in positive groups was significantly lower than that in control groups (65.1% vs 94.1%, P < 0.05). The tumor suppressing rate in test groups was 57.8%. After chemotherapy, the growth rate in test groups was lower than that in control groups (700.14 +/- 35.61 vs 1659.70 +/- 152.54, P < 0.05). Similar results were also observed under fluorescence microscope, and confirmed by Image-Pro Plus 4.5 analysis.CONCLUSION: pSUPER-ShRNA/mdr1 vector system allows simple, stable and durable nonviral knockdown of P-gp by RNAi in malignant cells and animals to restore their sensitivity to adriamycin. (C) 2009 The WJG Press and Baishideng. All rights reserved.

Inhibition of P-glycoprotein Over-expression by shRNA-mdr1b in Rat Astrocytes

Reversal of Mdr1b-dependent Multidrug Resistance in a Rat Astrocyte Model by Adenoviral-delivered Short Hairpin RNA

RNA interference inhibiting permeability glycoprotein over-expression in pharmaco-resistance rat astrocytes model

miR-485's anti-drug resistant epilepsy effects by regulating SV2A/PSD-95 and targeting ABCC1 and neuronal signaling-transduction proteins in hippocampus of rats

Suppression of the multidrug transporter P-glycoprotein using RNA interference in cultured rat astrocytes induced by coriaria lactone.

RNAi Inhibits Coriaria Lactone-Induced MDR1b Overexpression in Rat Brain Microvascular Endothelial Cells.

Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]

[Construction of Recombinant Adenovirus Vector for RNA Interference with Multidrug Resistance MDR1 Gene].

[Coriaria Lactone Induces in Vitro the Overexpression of Multidrug Resistance P-glycoprotein in Astrocyte from Rat Brain].

Inhibition of P-gp Expression in Amycin-resistant Human Erythroleukemia Cell Strain K562/ADM by Shrna Expression Vector

Study On Rna Interference Reversing Multidrug Resistance In K562/A02 Resistant Leukemia Cell.

Multidrug Resistance-Associated Protein 1 Decreases the Concentrations of Antiepileptic Drugs in Cortical Extracellular Fluid in Amygdale Kindling Rats

Reversal of MDR1 Gene-Dependent Multidrug Resistance Using Short Hairpin RNA Expression Vectors

Reversal of Multidrug Resistance by MDR1 Shrna Expression Vector in Human Leukemia K562/A02cells

Reversal of MDR1/P-glycoprotein-mediated Multidrug Resistance by Vector-Based RNA Interference in Vitro and in Vivo

Drug Resistance Reversal of Doxorubicin-resistant Human Leukemia Cell Line K562/ADM Through Down-regulating MDR1 Gene

Reversal of Multidrug Resistance by Magnetic Fe3o4 Nanoparticle Copolymerizating Daunorubicin and Mdr1 Shrna Expression Vector in Leukemia Cells

Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1

microRNA‐139‐5p confers sensitivity to antiepileptic drugs in refractory epilepsy by inhibition of MRP1

Overexpression of Human MRP1 in Neurons Causes Resistance to Antiepileptic Drugs Indrosophilaseizure Mutants

Reversal of Multi-Drug Resistance by Psuper-Shrna-mdr1 in Vivo and in Vitro.